How Does The DCT Model Increase Equity In Clinical Trials?

By Kyle Hogan

Over the past year and a half, the decentralized trial (DCT) model has helped many studies stay on track amid the disruption of the COVID-19 pandemic. In many ways, the pandemic has served as a real-world case study demonstrating this model’s advantages. And yet, the pandemic was not the genesis of decentralized trials. Decentralized trials emerged as a way to increase access to trials – making it possible for more (and more diverse) patients to enroll in studies.

That’s important for two main reasons.